Vivus: FDA Advisory Committee Panel Meeting for Qnexa has begun, stock halted (10.55 ) The Endocrinologic and Metabolic Drugs Advisory Committee to discuss Vivus's weight loss drug Qnexa has begun. Voting is expected to take place from 2-5pm. Trading in the stock has been halted and should remain so until the conclusion of the meeting.
Kurt Vonnegut wrote some great booksand had a great philosophy of life:
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.